BiotechTube

Placebo + PF-03654746

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Excessive Daytime Sleepiness

Conditions

Excessive Daytime Sleepiness, Narcolepsy

Trial Timeline

Nov 1, 2009 → Nov 1, 2010

NCT ID
NCT01006122

About Placebo + PF-03654746

Placebo + PF-03654746 is a phase 2 stage product being developed by Pfizer for Excessive Daytime Sleepiness. The current trial status is completed. This product is registered under clinical trial identifier NCT01006122. Target conditions include Excessive Daytime Sleepiness, Narcolepsy.

What happened to similar drugs?

2 of 5 similar drugs in Excessive Daytime Sleepiness were approved

Approved (2) Terminated (1) Active (3)
✅Solriamfetol + PlaceboAxsome TherapeuticsApproved
✅Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
🔄Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
🔄Fibrin Sealant Grifols + EVICELGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01006122Phase 2Completed

Competing Products

8 competing products in Excessive Daytime Sleepiness

See all competitors
ProductCompanyStageHype Score
JZP-110Jazz PharmaceuticalsPhase 2
32
Solriamfetol + PlaceboAxsome TherapeuticsApproved
40
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
32
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
37
ORX142 TabletsCentessa PharmaceuticalsPhase 1
33
VSF-173Vanda PharmaceuticalsPhase 2
25